CoChat
Sign Up
Cited by 176

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Bile acids, obesity, and the metabolic syndrome

Ma, Huijuan, Patti, Mary Elizabeth·2014·Best Practice & Research Clinical Gastroenterology
DOI 10.1016/j.bpg.2014.07.004PMC PMC4159616
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bpg.2014.07.004

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 8 references

Research works printed but not linked: 93

  1. Houten, 2006, Endocrine functions of bile acids, EMBO J, 25, 1419, 10.1038/sj.emboj.7601049 · DOI
  2. Chiang, 2013, Bile acid metabolism and signaling, Compr Physiol, 3, 1191, 10.1002/cphy.c120023 · DOI
  3. Kohli, 2013, Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids, J Clin Endocrinol Metab, 98, E708, 10.1210/jc.2012-3736 · DOI · Paper page
  4. Chiang, 2009, Bile acids: regulation of synthesis, J Lipid Res, 50, 1955, 10.1194/jlr.R900010-JLR200 · DOI · Paper page
  5. Chiang, 1998, Regulation of bile acid synthesis, Front Biosci, 3, d176, 10.2741/A273 · DOI
  6. Deo, 2008, Biotransformation of lithocholic acid by rat hepatic microsomes: metabolite analysis by liquid chromatography/mass spectrometry, Drug Metab Dispos, 36, 442, 10.1124/dmd.107.017533 · DOI
  7. Hofmann, 2008, Bile acids: chemistry, pathochemistry, biology, pathobiology, and therapeutics. Cellular and molecular life sciences, CMLS, 65, 2461, 10.1007/s00018-008-7568-6 · DOI
  8. Sayin, 2013, Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist, Cell Metab, 17, 225, 10.1016/j.cmet.2013.01.003 · DOI · Paper page
  9. Moschetta, 2005, A phylogenetic survey of biliary lipids in vertebrates, J lipid Res, 46, 2221, 10.1194/jlr.M500178-JLR200 · DOI
  10. Hofmann, 1964, The intraluminal phase of fat digestion in man: the lipid content of the micellar and oil phases of intestinal content obtained during fat digestion and absorption, J Clin Invest, 43, 247, 10.1172/JCI104909 · DOI
  11. Myant, 1977, Cholesterol 7 alpha-hydroxylase, J lipid Res, 18, 135, 10.1016/S0022-2275(20)41693-1 · DOI
  12. Sinal, 2000, Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis, Cell, 102, 731, 10.1016/S0092-8674(00)00062-3 · DOI · Paper page
  13. Holt, 2003, Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis, Genes Dev, 17, 1581, 10.1101/gad.1083503 · DOI
  14. Yu, 2002, Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice, Am J Pathol, 161, 2003, 10.1016/S0002-9440(10)64478-1 · DOI
  15. Xie, 2001, An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids, Proc Natl Acad Sci U S A, 98, 3375, 10.1073/pnas.051014398 · DOI
  16. Haeusler, 2012, Impaired generation of 12-hydroxylated bile acids links hepatic insulin signaling with dyslipidemia, Cell Metab, 15, 65, 10.1016/j.cmet.2011.11.010 · DOI
  17. Pathak, 2013, Retinoic acid-related orphan receptor alpha regulates diurnal rhythm and fasting induction of sterol 12alpha-hydroxylase in bile acid synthesis, J Biol Chem, 288, 37154, 10.1074/jbc.M113.485987 · DOI
  18. Parks, 1999, Bile acids: natural ligands for an orphan nuclear receptor, Science, 284, 1365, 10.1126/science.284.5418.1365 · DOI · Paper page
  19. Nervi, 1978, Bile acid pool changes and regulation of cholate synthesis in experimental diabetes, Biochim Biophys Acta, 529, 212, 10.1016/0005-2760(78)90064-4 · DOI
  20. Subbiah, 1984, Cholesterol 7 alpha-hydroxylase of rat liver: an insulin sensitive enzyme, Biochem Biophys Res Commun, 124, 896, 10.1016/0006-291X(84)91042-8 · DOI
  21. Lefebvre, 2009, Role of bile acids and bile acid receptors in metabolic regulation, Physiol Rev, 89, 147, 10.1152/physrev.00010.2008 · DOI · Paper page
  22. Nguyen, 2008, Bile acids and signal transduction: role in glucose homeostasis, Cell Signal, 20, 2180, 10.1016/j.cellsig.2008.06.014 · DOI
  23. Eloranta, 2008, The role of FXR in disorders of bile acid homeostasis, Physiology, 23, 286, 10.1152/physiol.00020.2008 · DOI
  24. Maruyama, 2002, Identification of membrane-type receptor for bile acids (M-BAR), Biochem Biophys Res Commun, 298, 714, 10.1016/S0006-291X(02)02550-0 · DOI · Paper page
  25. Vassileva, 2006, Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formation, Biochem J, 398, 423, 10.1042/BJ20060537 · DOI
  26. Angelin, 1978, Bile acid kinetics in relation to endogenous tryglyceride metabolism in various types of hyperlipoproteinemia, J lipid Res, 19, 1004, 10.1016/S0022-2275(20)40684-4 · DOI
  27. Angelin, 1978, Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia, J Lipid Res, 19, 1017, 10.1016/S0022-2275(20)40685-6 · DOI
  28. Sirvent, 2004, The farnesoid X receptor induces very low density lipoprotein receptor gene expression, FEBS Lett, 566, 173, 10.1016/j.febslet.2004.04.026 · DOI
  29. Watanabe, 2004, Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c, J Clin Invest, 113, 1408, 10.1172/JCI21025 · DOI
  30. Lambert, 2003, The farnesoid X-receptor is an essential regulator of cholesterol homeostasis, J Biol Chem, 278, 2563, 10.1074/jbc.M209525200 · DOI
  31. Hanniman, 2005, Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice, J lipid Res, 46, 2595, 10.1194/jlr.M500390-JLR200 · DOI
  32. Mencarelli, 2009, Antiatherosclerotic effect of farnesoid X receptor, Am J Physiol Heart Circ Physiol, 296, H272, 10.1152/ajpheart.01075.2008 · DOI
  33. Zhang, 2006, FXR deficiency causes reduced atherosclerosis in Ldlr−/− mice, Arterioscler Thrombo Vasc Biol, 26, 2316, 10.1161/01.ATV.0000235697.35431.05 · DOI
  34. Hartman, 2009, Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice, J Lipid Res, 50, 1090, 10.1194/jlr.M800619-JLR200 · DOI
  35. Pineda Torra, 2003, Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor, Mol Endocrinol, 17, 259, 10.1210/me.2002-0120 · DOI
  36. Savkur, 2005, Regulation of pyruvate dehydrogenase kinase expression by the farnesoid X receptor, Biochem Biophys Res Commun, 329, 391, 10.1016/j.bbrc.2005.01.141 · DOI
  37. Claudel, 2005, The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism, Arterioscler Thrombo Vasc Biol, 25, 2020, 10.1161/01.ATV.0000178994.21828.a7 · DOI
  38. Ozcan, 2006, Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes, Science, 313, 1137, 10.1126/science.1128294 · DOI · Paper page
  39. Cha, 2014, The role of tauroursodeoxycholic acid on adipogenesis of human adipose-derived stem cells by modulation of ER stress, Biomaterials, 35, 2851, 10.1016/j.biomaterials.2013.12.067 · DOI
  40. Malisova, 2013, Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes, PloS One, 8, e82086, 10.1371/journal.pone.0082086 · DOI
  41. Kobayashi, 2007, Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin, Diabetes, 56, 239, 10.2337/db06-0353 · DOI
  42. Ma, 2006, Farnesoid X receptor is essential for normal glucose homeostasis, J Clin Invest, 116, 1102, 10.1172/JCI25604 · DOI
  43. Zhang, 2006, Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice, Proc Natl Acad Sci U S A, 103, 1006, 10.1073/pnas.0506982103 · DOI
  44. Fang, 2007, Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling, Mol Pharmacol, 71, 1122, 10.1124/mol.106.032060 · DOI
  45. Bouscarel, 1993, Ursodeoxycholate mobilizes intracellular Ca2+ and activates phosphorylase a in isolated hepatocytes, Am J Physiol, 264, G243
  46. Li, 2010, Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice, Hepatology, 52, 678, 10.1002/hep.23721 · DOI
  47. Cipriani, 2010, FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats, J lipid Res, 51, 771, 10.1194/jlr.M001602 · DOI
  48. Yamagata, 2004, Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1, J Biol Chem, 279, 23158, 10.1074/jbc.M314322200 · DOI
  49. Renga, 2010, The bile acid sensor FXR regulates insulin transcription and secretion, Biochim Biophys Acta, 1802, 363, 10.1016/j.bbadis.2010.01.002 · DOI
  50. Cariou, 2006, The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice, J Biol Chem, 281, 11039, 10.1074/jbc.M510258200 · DOI
  51. Prawitt, 2011, Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity, Diabetes, 60, 1861, 10.2337/db11-0030 · DOI
  52. Katsuma, 2005, Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1, Biochem Biophys Res Commun, 329, 386, 10.1016/j.bbrc.2005.01.139 · DOI · Paper page
  53. Poole, 2010, Expression and function of the bile acid receptor GpBAR1 (TGR5) in the murine enteric nervous system, Neurogastroenterol Motil, 22, 814, 10.1111/j.1365-2982.2010.01487.x · DOI
  54. Mussig, 2009, Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus, Metabolism, 58, 1809, 10.1016/j.metabol.2009.06.012 · DOI
  55. Maruyama, 2006, Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice, J Endocrinol, 191, 197, 10.1677/joe.1.06546 · DOI
  56. Sato, 2007, Anti-hyperglycemic activity of a TGR5 agonist isolated from Olea europaea, Biochem Biophys Res Commun, 362, 793, 10.1016/j.bbrc.2007.06.130 · DOI
  57. Shaham, 2008, Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity, Mol Syst biol, 4, 214, 10.1038/msb.2008.50 · DOI · Paper page
  58. Cariou, 2011, Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults, Nutrition Metab, 8, 48, 10.1186/1743-7075-8-48 · DOI
  59. Haeusler, 2013, Human insulin resistance is associated with increased plasma levels of 12alpha-hydroxylated bile acids, Diabetes, 62, 4184, 10.2337/db13-0639 · DOI · Paper page
  60. Brufau, 2010, Improved glycemic control with colesevelam treatment in patients with type 2 diabetes is not directly associated with changes in bile acid metabolism, Hepatology, 52, 1455, 10.1002/hep.23831 · DOI
  61. Wewalka, 2014, Fasting serum taurine-conjugated bile acids are elevated in type 2 diabetes and do not change with intensification of insulin, J Clin Endocrinol Metab, 99, 1442, 10.1210/jc.2013-3367 · DOI
  62. Schauer, 2014, Bariatric surgery versus intensive medical therapy for diabetes - 3-year outcomes, N Engl J Med, 370, 2002, 10.1056/NEJMoa1401329 · DOI · Paper page
  63. Pournaras, 2012, The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control, Endocrinology, 153, 3613, 10.1210/en.2011-2145 · DOI · Paper page
  64. Gerhard, 2013, A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass, Diabetes Care, 36, 1859, 10.2337/dc12-2255 · DOI
  65. Steinert, 2013, Bile acids and gut peptide secretion after bariatric surgery: a 1-year prospective randomized pilot trial, Obesity, 21, E660, 10.1002/oby.20522 · DOI
  66. Bojsen-Moller, 2014, Early enhancements of hepatic and later of peripheral insulin sensitivity combined with increased postprandial insulin secretion contribute to improved glycemic control after Roux-en-Y gastric bypass, Diabetes, 63, 1725, 10.2337/db13-1307 · DOI
  67. Goldfine, 2006, Necdin and E2F4 are modulated by rosiglitazone therapy in diabetic human adipose and muscle tissue, Diabetes, 55, 640, 10.2337/diabetes.55.03.06.db05-1015 · DOI
  68. Myronovych, 2014, Vertical sleeve gastrectomy reduces hepatic steatosis while increasing serum bile acids in a weight-loss-independent manner, Obesity, 22, 390, 10.1002/oby.20548 · DOI
  69. Ryan, 2014, FXR is a molecular target for the effects of vertical sleeve gastrectomy, Nature, 509, 183, 10.1038/nature13135 · DOI · Paper page
  70. Ahmad, 2013, Roux-en-Y gastric bypass normalizes the blunted postprandial bile acid excursion associated with obesity, Int J Obes, 37, 1553, 10.1038/ijo.2013.38 · DOI · Paper page
  71. Pournaras, 2013, Are bile acids the new gut hormones? Lessons from weight loss surgery models, Endocrinology, 154, 2255, 10.1210/en.2013-1383 · DOI
  72. Duan, 2014, Mid to distal small bowel resection with the preservation of the terminal ileum improves glucose homeostasis in diabetic rats by activating the hindgut-dependent mechanism, J Gastrointest Surg, 18, 1186, 10.1007/s11605-014-2507-3 · DOI
  73. Cummings, 2013, Bile-acid-mediated decrease in endoplasmic reticulum stress: a potential contributor to the metabolic benefits of ileal interposition surgery in UCD-T2DM rats, Dis Models Mech, 6, 443, 10.1242/dmm.010421 · DOI
  74. Habegger, 2014, GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in rats, Diabetes, 63, 505, 10.2337/db13-0511 · DOI
  75. Liaset, 2011, Nutritional regulation of bile acid metabolism is associated with improved pathological characteristics of the metabolic syndrome, J Biol Chem, 286, 28382, 10.1074/jbc.M111.234732 · DOI
  76. Teodoro, 2013, Enhancement of brownfat thermogenesis using chenodeoxycholic acid in mice, Int J Obes, 1
  77. Staels, 2007, Bile acid sequestrants and the treatment of type 2 diabetes mellitus, Drugs, 67, 1383, 10.2165/00003495-200767100-00001 · DOI
  78. Fonseca, 2008, Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy, Diabetes Care, 31, 1479, 10.2337/dc08-0283 · DOI
  79. Watanabe, 2011, Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure, J Biol Chem, 286, 26913, 10.1074/jbc.M111.248203 · DOI
  80. Suzuki, 2007, Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia, J Nippon Med Sch, 74, 338, 10.1272/jnms.74.338 · DOI
  81. Shang, 2010, Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1, Am J Physiol Gastrointest Liver Physiol, 298, G419, 10.1152/ajpgi.00362.2009 · DOI
  82. Goldberg, 2008, Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy, Arch Intern Med, 168, 1531, 10.1001/archinte.168.14.1531 · DOI
  83. Beysen, 2012, Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study, Diabetologia, 55, 432, 10.1007/s00125-011-2382-3 · DOI
  84. Insull, 2006, Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review, South Med J, 99, 257, 10.1097/01.smj.0000208120.73327.db · DOI
  85. Watanabe, 2012, Bile acid binding resin improves metabolic control through the induction of energy expenditure, PloS One, 7, e38286, 10.1371/journal.pone.0038286 · DOI
  86. Harach, 2012, TGR5 POTENTIATES GLP-1 secretion in response to anionic exchange resins, Sci Reports, 2, 430, 10.1038/srep00430 · DOI
  87. Brufau, 2010, Plasma bile acids are not associated with energy metabolism in humans, Nutr Metab, 7, 73, 10.1186/1743-7075-7-73 · DOI
  88. Matsubara, 2013, FXR signaling in the enterohepatic system, Mol Cell Endocrinol, 368, 17, 10.1016/j.mce.2012.05.004 · DOI
  89. Stepanov, 2013, The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders, J Recept signal Transduct Res, 33, 213, 10.3109/10799893.2013.802805 · DOI
  90. Duboc, 2014, The bile acid TGR5 membrane receptor: from basic research to clinical application, Dig Liver Dis, 46, 302, 10.1016/j.dld.2013.10.021 · DOI · Paper page
  91. Costarelli, 2001, Acute effects of dietary fat composition on postprandial plasma bile acid and cholecystokinin concentrations in healthy premenopausal women, Br J Nutr, 86, 471, 10.1079/BJN2001431 · DOI
  92. Roager, 2014, NCFM affects vitamin E acetate metabolism and intestinal bile acid signature in monocolonized mice, Gut Microbes, 5
  93. Degirolamo, 2014, Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice, Cell Reports, 7, 12, 10.1016/j.celrep.2014.02.032 · DOI · Paper page

Cited by

Sorted by citations

See all 176

Metadata

Authors
Ma, H., & Patti, M. E.
Venue
Best Practice & Research Clinical Gastroenterology
Publisher
Elsevier BV
Published
2014-08
Volume
28
Issue
4
Pages
573-583
ISSN
1521-6918
DOI
10.1016/j.bpg.2014.07.004
PMC
PMC4159616
Cited by
176
References
8
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Hebei Health Department of Scientific Research Fund
  • DRC (Joslin Diabetes Center) (P30DK036836)
  • American Diabetes Association

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review